Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B210a25e177b7334400fc5d4ed699bb3f> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B210a25e177b7334400fc5d4ed699bb3f NCIT_P378 "NCI" @default.
- B210a25e177b7334400fc5d4ed699bb3f type Axiom @default.
- B210a25e177b7334400fc5d4ed699bb3f annotatedProperty IAO_0000115 @default.
- B210a25e177b7334400fc5d4ed699bb3f annotatedSource NCIT_C104055 @default.
- B210a25e177b7334400fc5d4ed699bb3f annotatedTarget "The acetate form of the 21-substituted-19-nor-progestin telapristone, an orally available selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, CDB-4124 competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities." @default.